SOURCE: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

June 14, 2016 07:59 ET

Pieris Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

BOSTON, MA--(Marketwired - June 14, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today its participation at the Roth Capital Partners 3rd Annual Healthcare Day in London and the JMP Securities Life Sciences Conference in New York City.

The Roth Capital Partners 3rd Annual Healthcare Day will take place on June 22, 2016 at the Dorchester Hotel in London, U.K. ROTH's Healthcare Day will give investors the opportunity to interact with senior management of a select group of Life Sciences companies. Pieris president and CEO, Stephen Yoder will be available for one-on-one meetings during the conference.

The JMP Securities Life Science Conference will take place on June 21 - 22, 2016 at the St. Regis Hotel in New York City. Dr. Louis Matis, SVP and Chief Development Officer and Darlene Deptula-Hicks, SVP and Chief Financial Officer are scheduled to present on June 21, 2016 at 12:00 ET and will be available for one-on-one meetings that day.

About Pieris

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information visit

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; projected timing and outcomes of clinical trials; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and the Company's Quarterly Reports on Form 10-Q.

Contact Information